A study of Pfizer’s experimental antiviral pill, paxlovid, has found the drug can cut hospitalisations and deaths from Covid by nearly 90%, the company has said.
The US firm’s encouraging results, which are not yet peer-reviewed, suggest oral pills that can be taken at home are poised to take an increasing burden off hospitals.
The company released the study data last Friday, a day after the UK medicines regulator announced it had approved molnupiravir (Lagevrio), a drug developed by Ridgeback Biotherapeutics and Merck Sharp and Dohme, as the first oral antiviral pill for Covid.
Under deals announced in October, the UK expects to receive 480,000 doses of molnupiravir this year, with 250,000 courses of paxlovid due in late January. Paxlovid is a combination of an antiviral drug with ritonavir, a…
